Influence of adjuvant mindfulness-based cognitive therapy (MBCT) on symptoms of post-traumatic stress disorder (PTSD) in veterans – results from a randomized control study
Mostafa Jasbi, D. Sadeghi Bahmani, G. Karami, Maryam Omidbeygi, M. Peyravi, Ailin Panahi, J. Mirzaee, E. Holsboer-trachsler, S. Brand
Cognitive Behaviour Therapy June 12, 2018 DOI: 10.1080/16506073.2018.1445773 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractAmong Iranian veterans of the Iran–Iraq war, adding mindfulness-based cognitive therapy (MBCT) to standard treatment with citalopram reduced symptoms of PTSD, depression, anxiety, and stress more than standard treatment alone. Forty-eight male veterans (average age 52.97 years) were randomly assigned to eight weekly group MBCT sessions or to socio-therapeutic meetings of equal frequency and duration. All participants continued citalopram (30–50 mg/day). After eight weeks, scores for PTSD re-experiencing, avoidance, negative mood and cognition, hyperarousal, depression, anxiety, and stress decreased in both groups, but the reductions were larger in the MBCT group. The data suggest MBCT as an effective adjuvant intervention.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 48 |
| Population | Male Iranian veterans of the Iran–Iraq war with PTSD |
| Interventions | Mindfulness-based cognitive therapy Citalopram |
| Dose | 30–50 mg/day |
| Duration | 8-week intervention |
| Keywords | Medicine Psychology |
| Key finding | Adding MBCT to standard citalopram treatment significantly reduced symptoms of PTSD, depression, anxiety, and stress among veterans compared to standard treatment alone. |
Abstract
Abstract Even 30 or more years after the end of a war, veterans can suffer from post-traumatic stress disorder (PTSD). In the present study, we explored the influence on symptoms of PTSD among Iranian veterans of the Iran–Iraq war of mindfulness-based cognitive therapy (MBCT) as add-on to a standard treatment with citalopram. Forty-eight male veterans with PTSD (mean age: 52.97 years) took part in this eight-week intervention study. Standard treatment for all patients consisted of citalopram (30–50 mg/day at therapeutic dosages). Patients were randomly assigned either to the treatment or to the control condition. Treatment involved MBCT delivered in group sessions once a week. Patients in the control condition met at the hospital with the same frequency and duration for socio-therapeutic events. At baseline and at study completion, patients completed questionnaires covering symptoms of PTSD, depression, anxiety, and stress. At study completion after eight weeks, scores for PTSD (re-experiencing events, avoidance, negative mood and cognition, hyperarousal), depression, anxiety, and stress were lower, but more so in the intervention than the control group. Data suggest that, as adjuvant to standard SSRI medication, MBCT is an effective intervention to significantly reduce symptoms of PTSD, depression, anxiety, and stress among veterans.